Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System

We sought to identify factors that are predictive of liver transplantation or death in patients with primary sclerosing cholangitis (PSC), and to develop and validate a contemporaneous risk score for use in a real‐world clinical setting. Analyzing data from 1,001 patients recruited to the UK‐PSC res...

Full description

Saved in:

Bibliographic Details
Published in:	Hepatology (Baltimore, Md.) Vol. 69; no. 5; pp. 2120 - 2135
Main Authors:	Goode, Elizabeth C., Clark, Allan B., Mells, George F., Srivastava, Brijesh, Spiess, Kelly, Gelson, William T.H., Trivedi, Palak J., Lynch, Kate D., Castren, Edit, Vesterhus, Mette N., Karlsen, Tom H., Ji, Sun‐Gou, Anderson, Carl A., Thorburn, Douglas, Hudson, Mark, Heneghan, Michael A., Aldersley, Mark A., Bathgate, Andrew, Sandford, Richard N., Alexander, Graeme J., Chapman, Roger W., Walmsley, Martine, Hirschfield, Gideon M., Rushbrook, Simon M.
Format:	Journal Article
Language:	English
Published:	United States Wolters Kluwer Health, Inc 01.05.2019 John Wiley and Sons Inc
Subjects:	Alkaline phosphatase Alkaline Phosphatase - blood Aspartate aminotransferase Bilirubin Cholangitis Cholangitis, Sclerosing - blood Cholangitis, Sclerosing - genetics Cholangitis, Sclerosing - mortality Cholangitis, Sclerosing - surgery Data processing Female Gallbladder diseases Hemorrhage Hepatology Heterozygosity Histocompatibility antigen HLA HLA Antigens - genetics Humans Liver Transplantation Male Middle Aged Original Phosphatase Platelets Risk Assessment Transplants & implants United Kingdom - epidemiology United Kingdom United Kingdom > UK
ISSN:	0270-9139, 1527-3350, 1527-3350
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	We sought to identify factors that are predictive of liver transplantation or death in patients with primary sclerosing cholangitis (PSC), and to develop and validate a contemporaneous risk score for use in a real‐world clinical setting. Analyzing data from 1,001 patients recruited to the UK‐PSC research cohort, we evaluated clinical variables for their association with 2‐year and 10‐year outcome through Cox‐proportional hazards and C‐statistic analyses. We generated risk scores for short‐term and long‐term outcome prediction, validating their use in two independent cohorts totaling 451 patients. Thirty‐six percent of the derivation cohort were transplanted or died over a cumulative follow‐up of 7,904 years. Serum alkaline phosphatase of at least 2.4 × upper limit of normal at 1 year after diagnosis was predictive of 10‐year outcome (hazard ratio [HR] = 3.05; C = 0.63; median transplant‐free survival 63 versus 108 months; P < 0.0001), as was the presence of extrahepatic biliary disease (HR = 1.45; P = 0.01). We developed two risk scoring systems based on age, values of bilirubin, alkaline phosphatase, albumin, platelets, presence of extrahepatic biliary disease, and variceal hemorrhage, which predicted 2‐year and 10‐year outcomes with good discrimination (C statistic = 0.81 and 0.80, respectively). Both UK‐PSC risk scores were well‐validated in our external cohort and outperformed the Mayo Clinic and aspartate aminotransferase‐to‐platelet ratio index (APRI) scores (C statistic = 0.75 and 0.63, respectively). Although heterozygosity for the previously validated human leukocyte antigen (HLA)‐DR*03:01 risk allele predicted increased risk of adverse outcome (HR = 1.33; P = 0.001), its addition did not improve the predictive accuracy of the UK‐PSC risk scores. Conclusion: Our analyses, based on a detailed clinical evaluation of a large representative cohort of participants with PSC, furthers our understanding of clinical risk markers and reports the development and validation of a real‐world scoring system to identify those patients most likely to die or require liver transplantation.
AbstractList	We sought to identify factors that are predictive of liver transplantation or death in patients with primary sclerosing cholangitis (PSC), and to develop and validate a contemporaneous risk score for use in a real‐world clinical setting. Analyzing data from 1,001 patients recruited to the UK‐PSC research cohort, we evaluated clinical variables for their association with 2‐year and 10‐year outcome through Cox‐proportional hazards and C‐statistic analyses. We generated risk scores for short‐term and long‐term outcome prediction, validating their use in two independent cohorts totaling 451 patients. Thirty‐six percent of the derivation cohort were transplanted or died over a cumulative follow‐up of 7,904 years. Serum alkaline phosphatase of at least 2.4 × upper limit of normal at 1 year after diagnosis was predictive of 10‐year outcome (hazard ratio [HR] = 3.05; C = 0.63; median transplant‐free survival 63 versus 108 months; P < 0.0001), as was the presence of extrahepatic biliary disease (HR = 1.45; P = 0.01). We developed two risk scoring systems based on age, values of bilirubin, alkaline phosphatase, albumin, platelets, presence of extrahepatic biliary disease, and variceal hemorrhage, which predicted 2‐year and 10‐year outcomes with good discrimination (C statistic = 0.81 and 0.80, respectively). Both UK‐PSC risk scores were well‐validated in our external cohort and outperformed the Mayo Clinic and aspartate aminotransferase‐to‐platelet ratio index (APRI) scores (C statistic = 0.75 and 0.63, respectively). Although heterozygosity for the previously validated human leukocyte antigen (HLA)‐DR03:01 risk allele predicted increased risk of adverse outcome (HR = 1.33; P = 0.001), its addition did not improve the predictive accuracy of the UK‐PSC risk scores. Conclusion: Our analyses, based on a detailed clinical evaluation of a large representative cohort of participants with PSC, furthers our understanding of clinical risk markers and reports the development and validation of a real‐world scoring system to identify those patients most likely to die or require liver transplantation. We sought to identify factors that are predictive of liver transplantation or death in patients with primary sclerosing cholangitis (PSC), and to develop and validate a contemporaneous risk score for use in a real-world clinical setting. Analyzing data from 1,001 patients recruited to the UK-PSC research cohort, we evaluated clinical variables for their association with 2-year and 10-year outcome through Cox-proportional hazards and C-statistic analyses. We generated risk scores for short-term and long-term outcome prediction, validating their use in two independent cohorts totaling 451 patients. Thirty-six percent of the derivation cohort were transplanted or died over a cumulative follow-up of 7,904 years. Serum alkaline phosphatase of at least 2.4 × upper limit of normal at 1 year after diagnosis was predictive of 10-year outcome (hazard ratio [HR] = 3.05; C = 0.63; median transplant-free survival 63 versus 108 months; P < 0.0001), as was the presence of extrahepatic biliary disease (HR = 1.45; P = 0.01). We developed two risk scoring systems based on age, values of bilirubin, alkaline phosphatase, albumin, platelets, presence of extrahepatic biliary disease, and variceal hemorrhage, which predicted 2-year and 10-year outcomes with good discrimination (C statistic = 0.81 and 0.80, respectively). Both UK-PSC risk scores were well-validated in our external cohort and outperformed the Mayo Clinic and aspartate aminotransferase-to-platelet ratio index (APRI) scores (C statistic = 0.75 and 0.63, respectively). Although heterozygosity for the previously validated human leukocyte antigen (HLA)-DR03:01 risk allele predicted increased risk of adverse outcome (HR = 1.33; P = 0.001), its addition did not improve the predictive accuracy of the UK-PSC risk scores. Conclusion: Our analyses, based on a detailed clinical evaluation of a large representative cohort of participants with PSC, furthers our understanding of clinical risk markers and reports the development and validation of a real-world scoring system to identify those patients most likely to die or require liver transplantation.We sought to identify factors that are predictive of liver transplantation or death in patients with primary sclerosing cholangitis (PSC), and to develop and validate a contemporaneous risk score for use in a real-world clinical setting. Analyzing data from 1,001 patients recruited to the UK-PSC research cohort, we evaluated clinical variables for their association with 2-year and 10-year outcome through Cox-proportional hazards and C-statistic analyses. We generated risk scores for short-term and long-term outcome prediction, validating their use in two independent cohorts totaling 451 patients. Thirty-six percent of the derivation cohort were transplanted or died over a cumulative follow-up of 7,904 years. Serum alkaline phosphatase of at least 2.4 × upper limit of normal at 1 year after diagnosis was predictive of 10-year outcome (hazard ratio [HR] = 3.05; C = 0.63; median transplant-free survival 63 versus 108 months; P < 0.0001), as was the presence of extrahepatic biliary disease (HR = 1.45; P = 0.01). We developed two risk scoring systems based on age, values of bilirubin, alkaline phosphatase, albumin, platelets, presence of extrahepatic biliary disease, and variceal hemorrhage, which predicted 2-year and 10-year outcomes with good discrimination (C statistic = 0.81 and 0.80, respectively). Both UK-PSC risk scores were well-validated in our external cohort and outperformed the Mayo Clinic and aspartate aminotransferase-to-platelet ratio index (APRI) scores (C statistic = 0.75 and 0.63, respectively). Although heterozygosity for the previously validated human leukocyte antigen (HLA)-DR*03:01 risk allele predicted increased risk of adverse outcome (HR = 1.33; P = 0.001), its addition did not improve the predictive accuracy of the UK-PSC risk scores. Conclusion: Our analyses, based on a detailed clinical evaluation of a large representative cohort of participants with PSC, furthers our understanding of clinical risk markers and reports the development and validation of a real-world scoring system to identify those patients most likely to die or require liver transplantation.
Author	Mells, George F. Ji, Sun‐Gou Clark, Allan B. Alexander, Graeme J. Thorburn, Douglas Goode, Elizabeth C. Hudson, Mark Srivastava, Brijesh Hirschfield, Gideon M. Castren, Edit Karlsen, Tom H. Sandford, Richard N. Rushbrook, Simon M. Spiess, Kelly Gelson, William T.H. Aldersley, Mark A. Chapman, Roger W. Walmsley, Martine Anderson, Carl A. Heneghan, Michael A. Trivedi, Palak J. Bathgate, Andrew Lynch, Kate D. Vesterhus, Mette N.
AuthorAffiliation	17 Scottish Liver Transplant Unit Royal Infirmary of Edinburgh Edinburgh United Kingdom 2 Academic Department of Medical Genetics Addenbrooke's Hospital, University of Cambridge Cambridge United Kingdom 9 Toronto Centre for Liver Disease University Health Network and University of Toronto Toronto Canada 12 Institute of Clinical Medicine, Faculty of Medicine University of Oslo Oslo Norway 6 National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre Birmingham United Kingdom 5 Cambridge Transplant Centre Addenbrooke's Hospital Cambridge United Kingdom 7 Institute of Immunology & Immunotherapy University of Birmingham Birmingham United Kingdom 14 Liver Medicine and Transplantation Service Freeman Hospital Newcastle United Kingdom 16 Department of Hepatology Leeds Teaching Hospital Leeds United Kingdom 18 PSC Support Oxfordshire United Kingdom 1 Norfolk and Norwich University Hospital Norwich United Kingdom 8 Centre for Rare Diseases, Institute of Translational Medicine Unive
AuthorAffiliation_xml	– name: 11 Norwegian PSC Research Center, Department of Transplantation Medicine Oslo University Hospital Rikshospitalet Oslo Norway – name: 16 Department of Hepatology Leeds Teaching Hospital Leeds United Kingdom – name: 13 Sheila Sherlock Liver Centre, Royal Free Hospital London United Kingdom – name: 17 Scottish Liver Transplant Unit Royal Infirmary of Edinburgh Edinburgh United Kingdom – name: 1 Norfolk and Norwich University Hospital Norwich United Kingdom – name: 15 Institute of Liver Studies Kings College Hospital London United Kingdom – name: 2 Academic Department of Medical Genetics Addenbrooke's Hospital, University of Cambridge Cambridge United Kingdom – name: 7 Institute of Immunology & Immunotherapy University of Birmingham Birmingham United Kingdom – name: 8 Centre for Rare Diseases, Institute of Translational Medicine University Hospitals Birmingham Birmingham United Kingdom – name: 4 Norwich Medical School University of East Anglia Norwich United Kingdom – name: 14 Liver Medicine and Transplantation Service Freeman Hospital Newcastle United Kingdom – name: 9 Toronto Centre for Liver Disease University Health Network and University of Toronto Toronto Canada – name: 6 National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre Birmingham United Kingdom – name: 5 Cambridge Transplant Centre Addenbrooke's Hospital Cambridge United Kingdom – name: 12 Institute of Clinical Medicine, Faculty of Medicine University of Oslo Oslo Norway – name: 10 Translational Gastroenterology Unit John Radcliffe Hospital, and Nuffield Department of Medicine, University of Oxford Oxford United Kingdom – name: 18 PSC Support Oxfordshire United Kingdom – name: 3 Wellcome Trust Sanger Institute Hinxton, Cambridge United Kingdom
Author_xml	– sequence: 1 givenname: Elizabeth C. orcidid: 0000-0002-8425-1530 surname: Goode fullname: Goode, Elizabeth C. email: ecg44@cam.ac.uk organization: Addenbrooke's Hospital – sequence: 2 givenname: Allan B. surname: Clark fullname: Clark, Allan B. organization: University of East Anglia – sequence: 3 givenname: George F. surname: Mells fullname: Mells, George F. organization: Addenbrooke's Hospital, University of Cambridge – sequence: 4 givenname: Brijesh surname: Srivastava fullname: Srivastava, Brijesh organization: Addenbrooke's Hospital, University of Cambridge – sequence: 5 givenname: Kelly surname: Spiess fullname: Spiess, Kelly organization: Addenbrooke's Hospital, University of Cambridge – sequence: 6 givenname: William T.H. surname: Gelson fullname: Gelson, William T.H. organization: Addenbrooke's Hospital – sequence: 7 givenname: Palak J. surname: Trivedi fullname: Trivedi, Palak J. organization: University Hospitals Birmingham – sequence: 8 givenname: Kate D. surname: Lynch fullname: Lynch, Kate D. organization: John Radcliffe Hospital, and Nuffield Department of Medicine, University of Oxford – sequence: 9 givenname: Edit surname: Castren fullname: Castren, Edit organization: Norfolk and Norwich University Hospital – sequence: 10 givenname: Mette N. surname: Vesterhus fullname: Vesterhus, Mette N. organization: University of Oslo – sequence: 11 givenname: Tom H. surname: Karlsen fullname: Karlsen, Tom H. organization: University of Oslo – sequence: 12 givenname: Sun‐Gou orcidid: 0000-0001-8652-6318 surname: Ji fullname: Ji, Sun‐Gou organization: Wellcome Trust Sanger Institute – sequence: 13 givenname: Carl A. surname: Anderson fullname: Anderson, Carl A. organization: Wellcome Trust Sanger Institute – sequence: 14 givenname: Douglas surname: Thorburn fullname: Thorburn, Douglas organization: Sheila Sherlock Liver Centre, Royal Free Hospital – sequence: 15 givenname: Mark surname: Hudson fullname: Hudson, Mark organization: Freeman Hospital – sequence: 16 givenname: Michael A. surname: Heneghan fullname: Heneghan, Michael A. organization: Kings College Hospital – sequence: 17 givenname: Mark A. surname: Aldersley fullname: Aldersley, Mark A. organization: Leeds Teaching Hospital – sequence: 18 givenname: Andrew surname: Bathgate fullname: Bathgate, Andrew organization: Royal Infirmary of Edinburgh – sequence: 19 givenname: Richard N. surname: Sandford fullname: Sandford, Richard N. organization: Addenbrooke's Hospital, University of Cambridge – sequence: 20 givenname: Graeme J. surname: Alexander fullname: Alexander, Graeme J. organization: Sheila Sherlock Liver Centre, Royal Free Hospital – sequence: 21 givenname: Roger W. surname: Chapman fullname: Chapman, Roger W. organization: John Radcliffe Hospital, and Nuffield Department of Medicine, University of Oxford – sequence: 22 givenname: Martine surname: Walmsley fullname: Walmsley, Martine organization: PSC Support – sequence: 24 givenname: Gideon M. surname: Hirschfield fullname: Hirschfield, Gideon M. organization: University Health Network and University of Toronto – sequence: 25 givenname: Simon M. surname: Rushbrook fullname: Rushbrook, Simon M. organization: University of East Anglia
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/30566748$$D View this record in MEDLINE/PubMed
BookMark	eNp9kt1u1DAQhS1URLeFC14AWeIGLtI6_onjG6RqaSlSpa4oP5eW40x2XZJ4GztF-wZ97Ho3pYJKcGVZ852jOTNzgPZ63wNCr3NylBNCj1ewPmKES_UMzXJBZcaYIHtoRqgkmcqZ2kcHIVwTQhSn5Qu0z4goCsnLGbo7Mzb6IeCTELx1JkKNf7i4wpdjtL6DgH2DFyY66GOYKovBdWbY4CvbwuCD65d4vvKt6ZcuuoBNX-OPcAutX3dJtPt_N62rk4nvt3YGf3HhZ9L7YSu-2oQI3Uv0vDFtgFcP7yH6dnb6dX6eXVx--jw_ucgs50xlhtJaVCBUaYFXdUoklCxLaiXJVVOqprKCCBCyqBiTYIHaXMhEmKpoqpqyQ_Rh8l2PVQe1TS0OptXrKZT2xum_K71b6aW_1YXIFeUiGbx7MBj8zQgh6s4FC20aAPgxaJoLxShjvEzo2yfotR-HPsXTlBKpmOBcJerNnx09tvJ7SQl4PwE2jTsM0DwiOdHbA9DpAPTuABJ7_IS1Lu4mn8K49n-KX66Fzb-t9fnpYlLcAwXdw3M
CitedBy_id	crossref_primary_10_4254_wjh_v15_i8_939 crossref_primary_10_1002_hep_31393 crossref_primary_10_1007_s10620_023_08260_1 crossref_primary_10_1097_HC9_0000000000000366 crossref_primary_10_1177_17562848241312766 crossref_primary_10_1016_j_cgh_2024_09_037 crossref_primary_10_1097_HEP_0000000000001268 crossref_primary_10_3390_jcm10194476 crossref_primary_10_4254_wjh_v13_i12_1828 crossref_primary_10_1007_s00330_020_06728_6 crossref_primary_10_1016_j_eclinm_2024_102526 crossref_primary_10_1016_j_clinre_2021_101827 crossref_primary_10_1007_s11901_020_00514_0 crossref_primary_10_1016_j_jhep_2020_02_033 crossref_primary_10_1002_hep_31069 crossref_primary_10_1002_jhbp_12117 crossref_primary_10_1002_hep_32771 crossref_primary_10_4254_wjh_v15_i9_1013 crossref_primary_10_1016_j_dld_2025_02_001 crossref_primary_10_1097_HC9_0000000000000590 crossref_primary_10_1136_flgastro_2022_102172 crossref_primary_10_1016_j_clinre_2023_102251 crossref_primary_10_1007_s00535_020_01681_z crossref_primary_10_1016_j_coph_2021_11_003 crossref_primary_10_1002_cld_902 crossref_primary_10_1007_s00535_020_01663_1 crossref_primary_10_1007_s00330_023_09915_3 crossref_primary_10_3390_jcm10245796 crossref_primary_10_1097_MEG_0000000000002516 crossref_primary_10_1097_MCG_0000000000002253 crossref_primary_10_1007_s00330_024_10787_4 crossref_primary_10_1111_liv_14326 crossref_primary_10_1016_j_jhep_2021_05_025 crossref_primary_10_1111_apt_17944 crossref_primary_10_1016_j_jceh_2021_03_006 crossref_primary_10_3748_wjg_v28_i21_2291 crossref_primary_10_1097_TXD_0000000000001774 crossref_primary_10_3390_diagnostics15172166 crossref_primary_10_1002_hep4_1860 crossref_primary_10_1111_apt_16296 crossref_primary_10_4103_jrms_jrms_813_22 crossref_primary_10_1016_j_cgh_2019_04_067 crossref_primary_10_1055_a_2255_7246 crossref_primary_10_3390_cells12232725 crossref_primary_10_1007_s10620_023_08262_z crossref_primary_10_1007_s00535_022_01914_3 crossref_primary_10_1053_j_gastro_2020_05_049 crossref_primary_10_1136_gutjnl_2020_322362 crossref_primary_10_1016_j_cgh_2023_04_004 crossref_primary_10_1097_MOG_0000000000000911 crossref_primary_10_1016_j_jhep_2022_05_011 crossref_primary_10_1016_j_clinre_2021_101775 crossref_primary_10_1097_HC9_0000000000000494 crossref_primary_10_3390_jcm13154548 crossref_primary_10_1007_s00108_024_01675_6 crossref_primary_10_1038_s41572_025_00600_x crossref_primary_10_1016_j_dld_2025_03_021 crossref_primary_10_1097_HEP_0000000000001172 crossref_primary_10_1155_2021_7746401 crossref_primary_10_3390_jcm14062098 crossref_primary_10_1111_1751_2980_12788 crossref_primary_10_1136_bmjopen_2024_095392 crossref_primary_10_1016_j_bpg_2023_101878 crossref_primary_10_3390_nu15030576 crossref_primary_10_3390_cells13191650 crossref_primary_10_1007_s10620_023_08003_2 crossref_primary_10_1002_hep_30964 crossref_primary_10_1111_apt_17251
Cites_doi	10.1002/hep.23294 10.1016/0016-5085(91)90673-9 10.1007/s00534-010-0319-8 10.1016/j.cgh.2012.12.032 10.1002/hep.26565 10.1136/gut.38.4.610 10.1186/1471-2288-13-33 10.1016/S1665-2681(19)30838-5 10.1016/S0025-6196(11)64614-4 10.1016/S0168-8278(01)00288-4 10.1016/j.cgh.2017.09.062 10.7326/L15-5093-2 10.1136/gutjnl-2016-313681 10.1053/j.gastro.2009.11.046 10.1053/j.gastro.2014.08.029 10.1093/aje/kwk052 10.1136/gut.51.5.731 10.1053/j.gastro.2013.12.030 10.1053/j.gastro.2017.02.038 10.1002/hep.28128 10.1016/0016-5085(92)91449-E 10.1016/j.dld.2010.12.008 10.1038/ng.3745 10.1016/j.jhep.2012.10.013 10.1097/MJT.0b013e3181c9dac6 10.1186/1741-7015-8-20 10.1002/hep.1840100406 10.1002/hep.24570 10.1038/ng.2616 10.1002/hep.27825 10.1016/j.jhep.2008.08.013 10.1002/hep.28017
ContentType	Journal Article
Copyright	2018 The Authors. Hepatology published by Wiley Periodicals, Inc. on behalf of American Association for the Study of Liver Diseases. 2019 by the American Association for the Study of Liver Diseases.
Copyright_xml	– notice: 2018 The Authors. Hepatology published by Wiley Periodicals, Inc. on behalf of American Association for the Study of Liver Diseases. – notice: 2019 by the American Association for the Study of Liver Diseases.
CorporateAuthor	UK-PSC Consortium
CorporateAuthor_xml	– name: UK-PSC Consortium
DBID	24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8 5PM
DOI	10.1002/hep.30479
DatabaseName	Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Nucleic Acids Abstracts MEDLINE - Academic
DatabaseTitleList	AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
DocumentTitleAlternate	Hepatology
EISSN	1527-3350
EndPage	2135
ExternalDocumentID	PMC6519245 30566748 10_1002_hep_30479 HEP30479
Genre	article Validation Study Research Support, Non-U.S. Gov't Journal Article
GeographicLocations	United Kingdom United Kingdom--UK
GeographicLocations_xml	– name: United Kingdom – name: United Kingdom--UK
GrantInformation_xml	– fundername: Isaac Newton Trust – fundername: Department of Health – fundername: Addenbrooke's Charitable Trust, Cambridge University Hospitals – fundername: National Institute of Health Research – fundername: Health Research – fundername: Norwegian PSC Research Center
GroupedDBID	--- --K .3N .55 .GA .GJ .Y3 05W 0R~ 10A 186 1B1 1CY 1L6 1OB 1OC 1ZS 1~5 24P 31~ 33P 3O- 3SF 3WU 4.4 4G. 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AALRI AANHP AAONW AAQFI AAQQT AAQXK AASGY AAXRX AAXUO AAZKR ABCQN ABCUV ABEML ABIJN ABLJU ABMAC ABOCM ABPVW ABWVN ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACLDA ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADMUD ADNMO ADOZA ADXAS ADZMN ADZOD AECAP AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFFNX AFGKR AFPWT AFUWQ AFZJQ AHMBA AIACR AIURR AIWBW AJAOE AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD F00 F01 F04 F5P FD8 FDB FEDTE FGOYB FUBAC G-S G.N GNP GODZA H.X HBH HF~ HHY HHZ HVGLF HZ~ IHE IX1 J0M J5H JPC KBYEO KQQ LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 M65 MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB NQ- O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K R2- RGB RIG RIWAO RJQFR ROL RPZ RWI RX1 RYL SEW SSZ SUPJJ TEORI UB1 V2E V9Y W2D W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WXI X7M XG1 XV2 ZGI ZXP ZZTAW ~IA ~WT 9DU AAMMB AAYXX ABJNI ACZKN ADSXY AEFGJ AFNMH AGQPQ AGXDD AHQVU AIDQK AIDYY AIQQE CITATION MEWTI O8X WXSBR ACIJW CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8 5PM
ID	FETCH-LOGICAL-c4439-a22d5be598ce4bd009597882c7019f89fbc505e576b337ece2c157788ab6fbd23
IEDL.DBID	24P
ISICitedReferencesCount	74
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000466449400021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0270-9139 1527-3350
IngestDate	Tue Sep 30 15:35:44 EDT 2025 Fri Sep 05 07:49:11 EDT 2025 Sat Nov 29 14:28:27 EST 2025 Wed Feb 19 02:24:05 EST 2025 Sat Nov 29 05:40:50 EST 2025 Tue Nov 18 19:51:19 EST 2025 Wed Jan 22 16:40:02 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	5
Language	English
License	Attribution-NonCommercial 2018 The Authors. Hepatology published by Wiley Periodicals, Inc. on behalf of American Association for the Study of Liver Diseases. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4439-a22d5be598ce4bd009597882c7019f89fbc505e576b337ece2c157788ab6fbd23
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 Potential conflict of interest: Dr. Bathgate received grants from Gilead. Dr. Hirschfield consults and received grants from Intercept; he consults for GlaxoSmithKline, Novartis, and Cymabay; he received grants from Gilead (to continue subsequent unrestricted support of the UK‐PSC cohort) and Falk. Dr. Rushbrook advises Falk and Intercept. Dr. Sandford received grants from Intercept. Dr. Vesterhus advises Intercept. Supported by the National Institute of Health Research (RD‐TRC and Birmingham Biomedical Research Centre); Isaac Newton Trust; Addenbrooke's Charitable Trust; Norwegian PSC Research Center; PSC Support; Lily and Terry Horner Chair in Autoimmune Liver Disease Research (to G.M.H.). E.C.G. is supported by a fellowship from the Wellcome Trust. These authors contributed equally to the work.
ORCID	0000-0002-8425-1530 0000-0001-8652-6318
OpenAccessLink	https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.30479
PMID	30566748
PQID	2207935449
PQPubID	996352
PageCount	0
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_6519245 proquest_miscellaneous_2159323348 proquest_journals_2207935449 pubmed_primary_30566748 crossref_primary_10_1002_hep_30479 crossref_citationtrail_10_1002_hep_30479 wiley_primary_10_1002_hep_30479_HEP30479
PublicationCentury	2000
PublicationDate	May 2019
PublicationDateYYYYMMDD	2019-05-01
PublicationDate_xml	– month: 05 year: 2019 text: May 2019
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: Hoboken
PublicationTitle	Hepatology (Baltimore, Md.)
PublicationTitleAlternate	Hepatology
PublicationYear	2019
Publisher	Wolters Kluwer Health, Inc John Wiley and Sons Inc
Publisher_xml	– name: Wolters Kluwer Health, Inc – name: John Wiley and Sons Inc
References	2015; 162 2002; 36 2013; 45 2017; 49 2002; 51 2007; 165 1992; 103 2011; 54 2017; 152 2018; 67 1996; 38 2011; 18 2013; 58 1989; 10 1991; 100 2013; 11 2009; 50 2010; 138 2015; 62 2013; 13 1995; 22 2000; 75 2016; 63 2011; 43 2014; 13 2014; 147 2018; 16 2010; 51 2014; 146 2010; 8 Weismuller (R2-27-20241017) 2017; 152 Karlsen (R6-27-20241017) 2010; 138 Bjornsson (R12-27-20241017) 2002; 51 Ji (R8-27-20241017) 2017; 49 Corpechot (R22-27-20241017) 2014; 146 Broome (R10-27-20241017) 1995; 22 Boonstra (R16-27-20241017) 2013; 58 Kim (R21-27-20241017) 2000; 75 Bjornsson (R11-27-20241017) 2011; 18 Mallett (R27-27-20241017) 2010; 8 Collins (R30-27-20241017) 2015; 162 Vesterhus (R23-27-20241017) 2015; 62 Farrant (R19-27-20241017) 1991; 100 de Vries (R24-27-20241017) 2018; 67 Lammers (R31-27-20241017) 2014; 13 Broome (R17-27-20241017) 1996; 38 Carbone (R29-27-20241017) 2016; 63 Claessen (R4-27-20241017) 2009; 50 Royston (R28-27-20241017) 2013; 13 Razumilava (R5-27-20241017) 2011; 54 Sano (R3-27-20241017) 2011; 18 Dickson (R20-27-20241017) 1992; 103 Webb (R33-27-20241017) 2018; 16 Liu (R7-27-20241017) 2013; 45 Stanich (R15-27-20241017) 2011; 43 Vittinghoff (R26-27-20241017) 2007; 165 Lindstrom (R14-27-20241017) 2013; 11 Wiesner (R18-27-20241017) 1989; 10 Chapman (R25-27-20241017) 2010; 51 Al Mamari (R13-27-20241017) 2013; 58 Lammers (R32-27-20241017) 2014; 147 Bergquist (R1-27-20241017) 2002; 36 Trivedi (R9-27-20241017) 2016; 63 31550385 - Hepatology. 2020 Jan;71(1):399-400 36719819 - Eur J Gastroenterol Hepatol. 2023 Apr 1;35(4):480-487 31544247 - Hepatology. 2020 Jan;71(1):398-399
References_xml	– volume: 51 start-page: 660 year: 2010 end-page: 678 article-title: Diagnosis and management of primary sclerosing cholangitis publication-title: Hepatology – volume: 51 start-page: 731 year: 2002 end-page: 735 article-title: Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis publication-title: Gut – volume: 58 start-page: 2045 year: 2013 end-page: 2055 article-title: Population‐based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis publication-title: Hepatology – volume: 38 start-page: 610 year: 1996 end-page: 615 article-title: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis publication-title: Gut – volume: 63 start-page: 644 year: 2016 end-page: 659 article-title: Risk stratification in autoimmune cholestatic liver diseases: opportunities for clinicians and trialists publication-title: Hepatology – volume: 45 start-page: 670 year: 2013 end-page: 675 article-title: Dense genotyping of immune‐related disease regions identifies nine new risk loci for primary sclerosing cholangitis publication-title: Nat Genet – volume: 54 start-page: 1842 year: 2011 end-page: 1852 article-title: Cancer surveillance in patients with primary sclerosing cholangitis publication-title: Hepatology – volume: 100 start-page: 1710 year: 1991 end-page: 1717 article-title: Natural history and prognostic variables in primary sclerosing cholangitis publication-title: Gastroenterology – volume: 162 start-page: 735 year: 2015 end-page: 736 article-title: Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) publication-title: Ann Intern Med – volume: 147 start-page: 1338 year: 2014 end-page: 1349 article-title: Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow‐up study publication-title: Gastroenterology – volume: 58 start-page: 329 year: 2013 end-page: 334 article-title: Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis publication-title: J Hepatol – volume: 10 start-page: 430 year: 1989 end-page: 436 article-title: Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis publication-title: Hepatology – volume: 16 start-page: 278 year: 2018 end-page: 287 article-title: Twenty‐year comparative analysis of patients with autoimmune liver diseases on transplant waitlists publication-title: Clin Gastroenterol Hepatol – volume: 22 start-page: 1404 year: 1995 end-page: 1408 article-title: Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential publication-title: Hepatology – volume: 49 start-page: 269 year: 2017 end-page: 273 article-title: Genome‐wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease publication-title: Nat Genet – volume: 63 start-page: 930 year: 2016 end-page: 950 article-title: The UK‐PBC risk scores: derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cirrhosis publication-title: Hepatology – volume: 138 start-page: 1102 year: 2010 end-page: 1111 article-title: Genome‐wide association analysis in primary sclerosing cholangitis publication-title: Gastroenterology – volume: 165 start-page: 710 year: 2007 end-page: 718 article-title: Relaxing the rule of ten events per variable in logistic and Cox regression publication-title: Am J Epidemiol – volume: 103 start-page: 1893 year: 1992 end-page: 1901 article-title: Primary sclerosing cholangitis: refinement and validation of survival models publication-title: Gastroenterology – volume: 13 start-page: 316 year: 2014 end-page: 326 article-title: Predicting outcome in primary biliary cirrhosis publication-title: Ann Hepatol – volume: 75 start-page: 688 year: 2000 end-page: 694 article-title: A revised natural history model for primary sclerosing cholangitis publication-title: Mayo Clin Proc – volume: 18 start-page: 198 year: 2011 end-page: 205 article-title: Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy publication-title: Am J Ther – volume: 18 start-page: 154 year: 2011 end-page: 161 article-title: Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis publication-title: J Hepatobiliary Pancreat Sci – volume: 8 start-page: 20 year: 2010 article-title: Reporting methods in studies developing prognostic models in cancer: a review publication-title: BMC Med – volume: 13 start-page: 33 year: 2013 article-title: External validation of a Cox prognostic model: principles and methods publication-title: BMC Med Res Methodol – volume: 36 start-page: 321 year: 2002 end-page: 327 article-title: Hepatic and extrahepatic malignancies in primary sclerosing cholangitis publication-title: J Hepatol – volume: 152 start-page: 1975 year: 2017 end-page: 1984 article-title: Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis publication-title: Gastroenterology – volume: 50 start-page: 158 year: 2009 end-page: 164 article-title: High lifetime risk of cancer in primary sclerosing cholangitis publication-title: J Hepatol – volume: 62 start-page: 188 year: 2015 end-page: 197 article-title: Enhanced liver fibrosis score predicts transplant‐free survival in primary sclerosing cholangitis publication-title: Hepatology – volume: 67 start-page: 1864 year: 2018 end-page: 1869 article-title: A novel prognostic model for transplant‐free survival in primary sclerosing cholangitis publication-title: Gut – volume: 11 start-page: 841 year: 2013 end-page: 846 article-title: Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis publication-title: Clin Gastroenterol Hepatol – volume: 43 start-page: 309 year: 2011 end-page: 313 article-title: Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis publication-title: Dig Liver Dis – volume: 146 start-page: 970 year: 2014 end-page: 979 article-title: Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis publication-title: Gastroenterology – volume: 51 start-page: 660 year: 2010 ident: R25-27-20241017 article-title: Diagnosis and management of primary sclerosing cholangitis publication-title: Hepatology doi: 10.1002/hep.23294 – volume: 100 start-page: 1710 year: 1991 ident: R19-27-20241017 article-title: Natural history and prognostic variables in primary sclerosing cholangitis publication-title: Gastroenterology doi: 10.1016/0016-5085(91)90673-9 – volume: 18 start-page: 154 year: 2011 ident: R3-27-20241017 article-title: Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis publication-title: J Hepatobiliary Pancreat Sci doi: 10.1007/s00534-010-0319-8 – volume: 11 start-page: 841 year: 2013 ident: R14-27-20241017 article-title: Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2012.12.032 – volume: 58 start-page: 2045 year: 2013 ident: R16-27-20241017 article-title: Population‐based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis publication-title: Hepatology doi: 10.1002/hep.26565 – volume: 38 start-page: 610 year: 1996 ident: R17-27-20241017 article-title: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis publication-title: Gut doi: 10.1136/gut.38.4.610 – volume: 13 start-page: 33 year: 2013 ident: R28-27-20241017 article-title: External validation of a Cox prognostic model: principles and methods publication-title: BMC Med Res Methodol doi: 10.1186/1471-2288-13-33 – volume: 13 start-page: 316 year: 2014 ident: R31-27-20241017 article-title: Predicting outcome in primary biliary cirrhosis publication-title: Ann Hepatol doi: 10.1016/S1665-2681(19)30838-5 – volume: 75 start-page: 688 year: 2000 ident: R21-27-20241017 article-title: A revised natural history model for primary sclerosing cholangitis publication-title: Mayo Clin Proc doi: 10.1016/S0025-6196(11)64614-4 – volume: 36 start-page: 321 year: 2002 ident: R1-27-20241017 article-title: Hepatic and extrahepatic malignancies in primary sclerosing cholangitis publication-title: J Hepatol doi: 10.1016/S0168-8278(01)00288-4 – volume: 16 start-page: 278 year: 2018 ident: R33-27-20241017 article-title: Twenty‐year comparative analysis of patients with autoimmune liver diseases on transplant waitlists publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2017.09.062 – volume: 162 start-page: 735 year: 2015 ident: R30-27-20241017 article-title: Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) publication-title: Ann Intern Med doi: 10.7326/L15-5093-2 – volume: 67 start-page: 1864 year: 2018 ident: R24-27-20241017 article-title: A novel prognostic model for transplant‐free survival in primary sclerosing cholangitis publication-title: Gut doi: 10.1136/gutjnl-2016-313681 – volume: 138 start-page: 1102 year: 2010 ident: R6-27-20241017 article-title: Genome‐wide association analysis in primary sclerosing cholangitis publication-title: Gastroenterology doi: 10.1053/j.gastro.2009.11.046 – volume: 147 start-page: 1338 year: 2014 ident: R32-27-20241017 article-title: Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow‐up study publication-title: Gastroenterology doi: 10.1053/j.gastro.2014.08.029 – volume: 165 start-page: 710 year: 2007 ident: R26-27-20241017 article-title: Relaxing the rule of ten events per variable in logistic and Cox regression publication-title: Am J Epidemiol doi: 10.1093/aje/kwk052 – volume: 51 start-page: 731 year: 2002 ident: R12-27-20241017 article-title: Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis publication-title: Gut doi: 10.1136/gut.51.5.731 – volume: 146 start-page: 970 year: 2014 ident: R22-27-20241017 article-title: Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis publication-title: Gastroenterology doi: 10.1053/j.gastro.2013.12.030 – volume: 152 start-page: 1975 year: 2017 ident: R2-27-20241017 article-title: Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis publication-title: Gastroenterology doi: 10.1053/j.gastro.2017.02.038 – volume: 63 start-page: 644 year: 2016 ident: R9-27-20241017 article-title: Risk stratification in autoimmune cholestatic liver diseases: opportunities for clinicians and trialists publication-title: Hepatology doi: 10.1002/hep.28128 – volume: 103 start-page: 1893 year: 1992 ident: R20-27-20241017 article-title: Primary sclerosing cholangitis: refinement and validation of survival models publication-title: Gastroenterology doi: 10.1016/0016-5085(92)91449-E – volume: 43 start-page: 309 year: 2011 ident: R15-27-20241017 article-title: Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis publication-title: Dig Liver Dis doi: 10.1016/j.dld.2010.12.008 – volume: 49 start-page: 269 year: 2017 ident: R8-27-20241017 article-title: Genome‐wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease publication-title: Nat Genet doi: 10.1038/ng.3745 – volume: 58 start-page: 329 year: 2013 ident: R13-27-20241017 article-title: Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis publication-title: J Hepatol doi: 10.1016/j.jhep.2012.10.013 – volume: 18 start-page: 198 year: 2011 ident: R11-27-20241017 article-title: Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy publication-title: Am J Ther doi: 10.1097/MJT.0b013e3181c9dac6 – volume: 8 start-page: 20 year: 2010 ident: R27-27-20241017 article-title: Reporting methods in studies developing prognostic models in cancer: a review publication-title: BMC Med doi: 10.1186/1741-7015-8-20 – volume: 22 start-page: 1404 year: 1995 ident: R10-27-20241017 article-title: Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential publication-title: Hepatology – volume: 10 start-page: 430 year: 1989 ident: R18-27-20241017 article-title: Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis publication-title: Hepatology doi: 10.1002/hep.1840100406 – volume: 54 start-page: 1842 year: 2011 ident: R5-27-20241017 article-title: Cancer surveillance in patients with primary sclerosing cholangitis publication-title: Hepatology doi: 10.1002/hep.24570 – volume: 45 start-page: 670 year: 2013 ident: R7-27-20241017 article-title: Dense genotyping of immune‐related disease regions identifies nine new risk loci for primary sclerosing cholangitis publication-title: Nat Genet doi: 10.1038/ng.2616 – volume: 62 start-page: 188 year: 2015 ident: R23-27-20241017 article-title: Enhanced liver fibrosis score predicts transplant‐free survival in primary sclerosing cholangitis publication-title: Hepatology doi: 10.1002/hep.27825 – volume: 50 start-page: 158 year: 2009 ident: R4-27-20241017 article-title: High lifetime risk of cancer in primary sclerosing cholangitis publication-title: J Hepatol doi: 10.1016/j.jhep.2008.08.013 – volume: 63 start-page: 930 year: 2016 ident: R29-27-20241017 article-title: The UK‐PBC risk scores: derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cirrhosis publication-title: Hepatology doi: 10.1002/hep.28017 – reference: 31550385 - Hepatology. 2020 Jan;71(1):399-400 – reference: 36719819 - Eur J Gastroenterol Hepatol. 2023 Apr 1;35(4):480-487 – reference: 31544247 - Hepatology. 2020 Jan;71(1):398-399
SSID	ssj0009428
Score	2.5620718
Snippet	We sought to identify factors that are predictive of liver transplantation or death in patients with primary sclerosing cholangitis (PSC), and to develop and...
SourceID	pubmedcentral proquest pubmed crossref wiley
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	2120
SubjectTerms	Alkaline phosphatase Alkaline Phosphatase - blood Aspartate aminotransferase Bilirubin Cholangitis Cholangitis, Sclerosing - blood Cholangitis, Sclerosing - genetics Cholangitis, Sclerosing - mortality Cholangitis, Sclerosing - surgery Data processing Female Gallbladder diseases Hemorrhage Hepatology Heterozygosity Histocompatibility antigen HLA HLA Antigens - genetics Humans Liver Transplantation Male Middle Aged Original Phosphatase Platelets Risk Assessment Transplants & implants United Kingdom - epidemiology
Title	Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System
URI	https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.30479 https://www.ncbi.nlm.nih.gov/pubmed/30566748 https://www.proquest.com/docview/2207935449 https://www.proquest.com/docview/2159323348 https://pubmed.ncbi.nlm.nih.gov/PMC6519245
Volume	69
WOSCitedRecordID	wos000466449400021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1527-3350 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009428 issn: 0270-9139 databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT-MwEB6xsFpx4bG8yksG7WEvEa2T4EScEFBx4BHBwvYWObajVqAUkZbfwM9mxk4CFSAhcYkSeez4MRN_E9vfAPwRUhPxVdtrk6eDSpF7kdGRp3xDqz5SBJbA9PZMXFxEvV6cTMFBfRbG8UM0P9zIMuz3mgxcZuXeK2lo36DDTgTpP2Cm0_EFqTQPklfG3cAGVkW3q03Ly3FNK9Tme03WycnoHcJ8v1HyLYC1M1B3_lt1X4C5CniyQ6cpizBlit_w67xaWl-C566LvMPqATOa_R-M-uxyPMLiTcmGOUscC2vpUhLHVMGusUBsH06C7IhcZQqBNCiZLDR7syfJPt8i7HdRnKg4ya4G5R3mt7sAmWNPX4ab7sm_o1OvCtPgqQDhjCc512FmwjhSJsi05TpGx5orYnrPozjPFMIsg45N5vvCKMNVJxQoIbP9PNPcX4HpYliYNWCB0FzHgYwiLLqjcFIwQkuuFQIzHoeyBX_r8UpVxWFOoTTuU8e-zFPs2dT2bAt2G9EH1x0fCW3Wg55WtlumnBNpICowJu80yWh1tJQiCzMcowyiQJ_TKeYWrDodad5CThmFcGmBmNCeRoAYvSdTikHfMnvvh-QPh9hMqz2fVzw9PUnszfrXRTdgFtFe7HZrbsL06HFstuCnekKVeNy2xoNX0Yu2Yeb4qntz9gJX-SEJ
linkProvider	Wiley-Blackwell
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED-NDjFexvfWrYBBPPAStXOSJZF4QV2rItpSlbX0LXJsR402pdPS8jfwZ3NnJ1mrgYTEWyKfHX_cxb_zx-8APgRCEfFVx-mQp4NKkTqhVqEjXU27PiLwDIHpfBiMx-FiEU324FN1F8byQ9QLbmQZ5n9NBk4L0u071tClRo-dGNIfwL6HauQ3YP9i2p8N70h3PRNbFT2vDu0wRxWzUIe368y789E9kHn_rOQ2hjWTUP_J_1X_KRyW4JN9ttryDPZ0_hwejcrt9Rfwq2-j77Bq0LRiP7L1kn3brLF8XbBVyiaWibWwKRPLVsG-Y4HYQJwIWZfcZQqDlBVM5IptnUsy73OE_jaSExUn2DQrrjC_OQnILIP6S5j1e5fdgVOGanCkh5DGEZwrP9F-FErtJcrwHaNzzSWxvadhlCYSoZZG5yZx3UBLzeWZH6CESM7TRHH3FTTyVa6PgXmB4iryRBhi0WcSJwYdKMGVRHDGI1804WM1YLEsecwpnMZ1bBmYeYw9G5uebcL7WvTGdsefhFrVqMel_RYx50QciEqMye_qZLQ82k4RuV5tUAaRoMvpJnMTjqyS1F8hx4zCuDQh2FGfWoBYvXdT8mxp2L3PffKJfWymUZ-_Vzwe9Cbm4eTfRd_CweByNIyHX8ZfT-Exor_Int5sQWN9u9Gv4aH8iepx-6a0pd_D0CP-
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1fT9swEMBPDFC1lwH7mwHDm3jYS9TWSUgi7WViREWwLmKs9C1ybEetNqWItPsM-9i7s5OUqkNC2lsiXxzHvovvYud3AMehUAS-6rk9inRQKQo30ipypadp1UeEvgGYji7D4TAaj-N0Az41_8JYPkT7wY0sw7yvycD1rSq6S2roRGPEToT0J7DlB_iOJa6zny6Ru77JrIpxV4_Wl-OGK9Tj3fbS1dlozcVc3yl534M1U1Cy83-N34VntevJPltd2YMNXT6Hztd6cf0F_Els7h3WDJlW7GY6n7BviznWrys2K1hqOayVLUktq4J9xwrxAXEaZKcULFMSpGnFRKnYvV1J5nyEjr_N40TVCXY1rX7i9WYfILP89JfwIzm7Ph24daIGV_ro0LiCcxXkOogjqf1cGdoxhtZcEuu9iOIil-hoaQxtcs8LtdRc9oMQJUR-UuSKe69gs5yV-g0wP1Rcxb6IIqy6L3Fa0KESXEl0zXgcCAc-NgOWyZpiTsk0fmWWv8wz7NnM9KwDH1rRW9sd_xI6aEY9q623yjgnbCCqMBa_b4vR7mgxRZR6tkAZ9AM9Tv8xO_DaKkl7FwrLKImLA-GK-rQCxPReLSmnE8P2PgkoIg7wMY36PNzwbHCWmoO3jxc9gk76Jckuz4cX-_AUXb_Ybt08gM353UIfwrb8jdpx984Y0l_7xiHn
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Factors+Associated+With+Outcomes+of+Patients+With+Primary+Sclerosing+Cholangitis+and+Development+and+Validation+of+a+Risk+Scoring+System&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Goode%2C+Elizabeth+C.&rft.au=Clark%2C+Allan+B.&rft.au=Mells%2C+George+F.&rft.au=Srivastava%2C+Brijesh&rft.date=2019-05-01&rft.issn=0270-9139&rft.volume=69&rft.issue=5&rft.spage=2120&rft.epage=2135&rft_id=info:doi/10.1002%2Fhep.30479&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_hep_30479
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon